Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19—Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT)

Background: To date, no oral antiviral drug has proven to be beneficial in hospitalized patients with COVID-19. Methods: In this randomized, controlled, open-label, platform trial, we randomly assigned patients ≥18 years hospitalized with COVID-19 pneumonia to receive either camostat mesylate (CM) (...

Descripción completa

Detalles Bibliográficos
Autores principales: Karolyi, M., Pawelka, E., Omid, S., Koenig, F., Kauer, V., Rumpf, B., Hoepler, W., Kuran, A., Laferl, H., Seitz, T., Traugott, M., Rathkolb, V., Mueller, M., Abrahamowicz, A., Schoergenhofer, C., Hecking, M., Assinger, A., Wenisch, C., Zeitlinger, M., Jilma, B., Zoufaly, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354138/
https://www.ncbi.nlm.nih.gov/pubmed/35935856
http://dx.doi.org/10.3389/fphar.2022.870493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354138/
https://www.ncbi.nlm.nih.gov/pubmed/35935856
http://dx.doi.org/10.3389/fphar.2022.870493

Ejemplares similares